Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Post by Thao977on May 03, 2019 6:22pm
166 Views
Post# 29709382

From les affaires winner of the week

From les affaires winner of the week They forgot To talk about previous bad weeks Theratechnologies (+3,65%) La qubcoise Theratechnologies a profit cette semaine de la diffusion de ses derniers rsultats de vente de mdicaments, tel que rapport mensuellement par lanalyste Dewey Steadman, de Canaccord Genuity. En mars, lEgrifta a connu une hausse de volume vendu de 4,2% et de revenus de 16,7% par rapport lanne dernire. Le Trogarzo, nouvellement lanc, a connu une hausse plus modeste de volume de 1% et de revenus de 1,8% par rapport au mois prcdent, une situation qui ne semble pas inquiter lanalyste. En fin de parcours, laction de Theratechnologies aura progress de 0,25$, ou de 3,65%. En cours de semaine, le cours de son action a dbut 6,85$ pour clturer 7,10$.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse